(Q37699644)

22 August 2017

1 reference

title

Post-licensure monitoring of HPV vaccine in the United States (English)

1 reference

22 August 2017

1 reference

1 reference

United States of America

1 reference

3

Elizabeth R Unger

1 reference

22 August 2017

1

Lauri E Markowitz

1 reference

22 August 2017

4

Mona Saraiya

1 reference

22 August 2017

2

Susan Hariri

1 reference

22 August 2017

5

S Deblina Datta

1 reference

22 August 2017

Eileen F Dunne

6

1 reference

PubMed ID

20188681

22 August 2017

language of work or name

English

0 references

publication date

25 February 2010

1 reference

22 August 2017

1 reference

22 August 2017

28

1 reference

22 August 2017

30

1 reference

22 August 2017

4731-4737

1 reference

Monitoring the impact of vaccines postlicensure: new challenges, new opportunities

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

National Immunization Survey: the methodology of a vaccination surveillance system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Determining accurate vaccination coverage rates for adolescents: the National Immunization Survey-Teen 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human papillomavirus and cervical cancer behavioral surveillance in the US.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

The Vaccine Safety Datalink project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Real-time vaccine safety surveillance for the early detection of adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985-2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Diagnoses and outcomes in cervical cancer screening: a population-based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Development and duration of human papillomavirus lesions, after initial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

The health and economic burden of genital warts in a set of private health plans in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999--2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Prevalence of HPV infection among females in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Cervical cancer screening in the early post vaccine era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Accuracy of self-reported cancer-screening histories: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Some methodologic lessons learned from cancer screening research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

National registry for juvenile-onset recurrent respiratory papillomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.019

10.1016/J.VACCINE.2010.02.019

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20188681